Nilotinib hydrochloride monohydrate

Base Information

• Chemical Name: Nilotinib hydrochloride monohydrate
• CAS No.: 923288-90-8
• Molecular Formula: C28H25ClF3N7O2
• Molecular Weight: 584
• European Community (EC) Number: 692-062-6
• UNII: 5JHU0N1R6K
• ChEMBL ID: CHEMBL1201740
• DSSTox Substance ID: DTXSID00238967
• NCI Thesaurus Code: C95229
• Wikidata: Q27262451
• Mol file: 923288-90-8.mol

Synonyms:4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;AMN 107;AMN-107;AMN107;benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1);benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride, hydrate;benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride, hydrate (1:1:2);benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride, hydrate (1:2:2);benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride, hydrate (2:2:3);nilotinib;nilotinib dihydrochloride dihydrate;nilotinib hydrochloride;nilotinib hydrochloride anhydrous;nilotinib hydrochloride dihydrate;nilotinib hydrochloride hydrate;nilotinib hydrochloride monohydrate;nilotinib hydrochloride sesquihydrate;Tasigna

Chemical Property of Nilotinib hydrochloride monohydrate

Chemical Property:

• Appearance/Colour: White solid
• PSA: 101.11000
• LogP: 6.81280
• Storage Temp.: -20°C Freezer
• Solubility.: Aqueous Acid (Slightly), DMSO (Slightly), Ethanol (Slightly, Heated)
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 10
• Rotatable Bond Count: 6
• Exact Mass: 583.1710352
• Heavy Atom Count: 41
• Complexity: 817

Purity/Quality:

99%min ^*data from raw suppliers

NilotinibMonohydrochlorideMonohydrate ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.O.Cl
• Recent ClinicalTrials: Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
• Recent EU Clinical Trials: A phase 3 randomised non-inferiority trial to evaluate the use of imatinib, nilotinib and ponatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia
• description: Nilotinib Hydrochloride Monohydrate is the monohydrate monohydrochloride form of nilotinib, an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, upon administration, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl portion of the Bcr-Abl fusion protein, resulting in the inhibition of the constitutive kinase activity of Bcr-Abl protein. This inhibits the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. Nilotinib also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R; PDGFR), mast/stem cell growth factor receptor Kit (c-Kit), and, to a lesser extent, colony-stimulating factor 1 receptor (CSF-1R; CSF1R), and discoidin domain-containing receptor 1 (DDR1).Nilotinib Hydrochloride Monohydrate (Code C95229)
• Clinical Use: Nilotinib hydrochloride monohydrate was approved by FDA in 2007 for the treatment of chronic and accelerated phase Ph chromosome-positive CML adult patients which have developed resistance or intolerance to prior therapy that included imatinib. In 2012, apart from these previous indications, nilotinib hydrochloride monohydrate has also been indicated for the treatment of newly diagnosed adult patients with Ph chromosome-positive CML in chronic phase.
• Uses: Nilotinib Monohydrochloride Monohydrate might be useful in treatment of chronic myelogenous leukemia. It is a COVID19-related research product.

Technology Process of Nilotinib hydrochloride monohydrate

There total 1 articles about Nilotinib hydrochloride monohydrate which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

nilotinib (641571-10-0) → 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide monohydrochloride monohydrate (923288-90-8)

Guidance literature:

With hydrogenchloride; water; In methanol; at 30 - 50 ℃; for 0.75h; Product distribution / selectivity;

upstream raw materials:

nilotinib

Refernces

• 1、 -. "SALTS OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE". Page/Page column 10-11. . Retrieved 2008/06/13.